INT12398

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.39
First Reported 1991
Last Reported 2010
Negated 4
Speculated 6
Reported most in Abstract
Documents 11
Total Number 16
Disease Relevance 1.80
Pain Relevance 9.47

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Flvcr2) transmembrane transport (Flvcr2)
Anatomy Link Frequency
plasma 1
blood 1
NAc 1
substantia nigra 1
retina 1
Flvcr2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Dopamine 340 100.00 Very High Very High Very High
Serotonin 106 100.00 Very High Very High Very High
Glutamate 31 100.00 Very High Very High Very High
Intracerebroventricular 1 100.00 Very High Very High Very High
antidepressant 108 99.98 Very High Very High Very High
monoamine 21 99.98 Very High Very High Very High
Desipramine 17 99.82 Very High Very High Very High
cocaine 23 99.70 Very High Very High Very High
withdrawal 10 99.44 Very High Very High Very High
Gabapentin 164 99.28 Very High Very High Very High
Disease Link Frequency Relevance Heat
Recurrence 6 98.80 Very High Very High Very High
Morphine Dependence 1 98.68 Very High Very High Very High
Attention Deficit Hyperactivity Disorder 170 96.92 Very High Very High Very High
Neurological Disease 2 92.76 High High
Nervous System Injury 1 88.44 High High
Endometriosis (extended) 16 86.48 High High
Pheochromocytoma 4 80.80 Quite High
Pressure And Volume Under Development 3 79.76 Quite High
Diabetes Mellitus 7 78.96 Quite High
Substance Withdrawal Syndrome 1 75.00 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In this study, we examined the effect of intracerebroventricular (i.c.v.) administration of a potent glutamate transporter inhibitor, DL-threo-beta-benzyloxyaspartate (DL-TBOA), on acute morphine-induced antinociception, expression of somatic and negative affective components of morphine withdrawal, and acquisition of morphine-induced conditioned place preference in rats.
Spec (examined) Regulation (effect) of transporter associated with antinociception, glutamate, withdrawal, intracerebroventricular and morphine
1) Confidence 0.39 Published 2004 Journal Eur. J. Pharmacol. Section Abstract Doc Link 14757142 Disease Relevance 0.17 Pain Relevance 1.15
Monoamine transporter expression was differentially altered by cocaine; dopamine transporter mRNA levels in the ventral tegmental area, but not in the substantia nigra, were increased following withdrawal from cocaine, suggesting a role for the upregulated mesolimbic dopamine transporter in the mechanisms underlying relapse to cocaine taking.
Regulation (role) of transporter in substantia nigra associated with ventral tegmentum, dopamine, substantia nigra, withdrawal, recurrence, cocaine and monoamine
2) Confidence 0.30 Published 2000 Journal Brain Res. Mol. Brain Res. Section Abstract Doc Link 11072100 Disease Relevance 0.10 Pain Relevance 1.36
These results thus suggest that long-term administration of DMI did not affect the function of the NE transporter but reduced the number of DMI binding sites.
Neg (not) Regulation (affect) of NE transporter associated with desipramine
3) Confidence 0.19 Published 1991 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 1646320 Disease Relevance 0 Pain Relevance 0.86
Our results demonstrating serotonin transporter messenger RNA in the craniofacial and cardiac areas identify this gene product as the transporter most likely responsible for the previously identified accumulation of serotonin in skin and tooth germ [Lauder J.
Spec (likely) Regulation (responsible) of transporter in tooth germ associated with serotonin
4) Confidence 0.17 Published 1999 Journal Neuroscience Section Abstract Doc Link 10051233 Disease Relevance 0 Pain Relevance 0.59
Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone.
Regulation (Involvement) of transporter in blood associated with oxycodone
5) Confidence 0.09 Published 2008 Journal Drug Metab. Dispos. Section Title Doc Link 18606742 Disease Relevance 0 Pain Relevance 0.52
The addition of the ribosomal protein synthesis inhibitor, cycloheximide, abolished these effects (Shinkai et al 2005) suggesting that up-regulation of NE transporter function following prolonged exposure to milnacipran, probably results from post-transcriptional modifications.
Regulation (regulation) of transporter
6) Confidence 0.08 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2654524 Disease Relevance 0 Pain Relevance 0
Our results demonstrating serotonin transporter messenger RNA in the craniofacial and cardiac areas identify this gene product as the transporter most likely responsible for the previously identified accumulation of serotonin in skin and tooth germ [Lauder J.
Spec (likely) Regulation (responsible) of transporter in skin associated with serotonin
7) Confidence 0.06 Published 1999 Journal Neuroscience Section Abstract Doc Link 10051233 Disease Relevance 0 Pain Relevance 0.59
RESULTS: In rat retina, ischemic insult followed by reperfusion resulted in enhanced FAAH activity and protein expression paralleled by a significant decrease in the endogenous AEA tone, whereas the AEA-membrane transporter or the AEA-synthase NAPE-PLD (N-acyl-phosphatidylethanolamine-hydrolyzing-phospholipase-d) were not affected.
Neg (not) Regulation (affected) of transporter in retina
8) Confidence 0.05 Published 2007 Journal Invest. Ophthalmol. Vis. Sci. Section Body Doc Link 17591864 Disease Relevance 0 Pain Relevance 0
This property of amphetamine relies on its actions at the dopamine transporter (DAT), a presynaptic plasma membrane protein that is responsible for the reuptake of extracellular dopamine.
Regulation (responsible) of transporter in plasma associated with dopamine
9) Confidence 0.04 Published 2007 Journal PLoS Biology Section Abstract Doc Link PMC2020502 Disease Relevance 0.08 Pain Relevance 0.27
Initially, it was not clear whether activity at a single monoamine transporter affected the efficacy of this class of medication, especially for the treatment of more severely ill patients.
Neg (not) Spec (whether) Regulation (affected) of transporter associated with monoamine
10) Confidence 0.04 Published 2010 Journal Core evidence Section Body Doc Link PMC2899788 Disease Relevance 0.52 Pain Relevance 0.60
In the present study, we examined the effects of gene transfer of a glial glutamate transporter, GLT-1, into the NAc shell by recombinant adenoviruses on methamphetamine- and morphine-induced conditioned place preference in rats.
Spec (examined) Regulation (effects) of transporter in NAc associated with nucleus accumbens, glutamate and morphine
11) Confidence 0.04 Published 2005 Journal Eur. J. Neurosci. Section Abstract Doc Link 16324108 Disease Relevance 0 Pain Relevance 0.88
Suman-Chauhan and coworkers identified a high-affinity binding site for gabapentin in rat brain homogenate.38 Binding to this receptor was dependent on the system L transporter, indicating that gabapentin likely crosses the cell membrane and binding occurs intracellularly.
Regulation (dependent) of transporter in brain associated with gabapentin
12) Confidence 0.01 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2874339 Disease Relevance 0.09 Pain Relevance 1.43
Antidepressants targeting the serotonin reuptake transporter act via a competitive mechanism.
Regulation (targeting) of transporter associated with antidepressant and serotonin
13) Confidence 0.01 Published 2008 Journal J. Pharmacol. Exp. Ther. Section Title Doc Link 18801947 Disease Relevance 0 Pain Relevance 0.38
Evidence obtained from animal models suggests that psychostimulants may not be acting on the dopamine transporter to produce the expected increase in extracellular dopamine concentration in ADHD.
Neg (not) Spec (may) Regulation (acting) of transporter associated with dopamine and attention deficit hyperactivity disorder
14) Confidence 0.01 Published 2005 Journal Behav Brain Funct Section Abstract Doc Link PMC1180819 Disease Relevance 0.51 Pain Relevance 0.35
Understanding a mechanistic role for estrogens in modulating this transporter should suggest new therapeutic targets and regimens tailored for female vs. male patients in the treatment of behavioral disturbances exacerbated by fluctuating estrogens.


Regulation (modulating) of transporter
15) Confidence 0.00 Published 2006 Journal J Mol Signal Section Body Doc Link PMC1769494 Disease Relevance 0.16 Pain Relevance 0.27
Estradiol effects on the dopamine transporter – protein levels, subcellular location, and function

Background

Regulation (effects) of transporter associated with dopamine
16) Confidence 0.00 Published 2006 Journal J Mol Signal Section Title Doc Link PMC1769494 Disease Relevance 0.18 Pain Relevance 0.23

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox